Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18927047 | Stable, concentrated radionuclide complex solutions | October 2024 | May 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 18927034 | Stable, concentrated radionuclide complex solutions | October 2024 | February 2025 | Abandon | 4 | 0 | 0 | No | No |
| 18640884 | Stable, concentrated radionuclide complex solutions | April 2024 | September 2024 | Allow | 5 | 0 | 0 | Yes | No |
| 18640917 | Stable, concentrated radionuclide complex solutions | April 2024 | October 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18640907 | Stable, concentrated radionuclide complex solutions | April 2024 | October 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18640891 | Stable, concentrated radionuclide complex solutions | April 2024 | October 2024 | Allow | 6 | 0 | 0 | Yes | No |
| 18612564 | LIPIDS AND COMPOSITIONS THEREOF | March 2024 | January 2025 | Allow | 10 | 1 | 0 | Yes | No |
| 18585905 | IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) | February 2024 | August 2024 | Allow | 6 | 0 | 0 | No | No |
| 18410875 | Cationic Lipid Compound and Composition for Delivery of Nucleic Acids and Use Thereof | January 2024 | October 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18572198 | PREPARATION METHOD OF NANOZYME COMPOSITE-BASED HYBRID HYDROGEL EYE DROP | December 2023 | July 2024 | Allow | 6 | 0 | 0 | No | No |
| 18526168 | Method to Improve the Encapsulation Efficiency and Physicochemical Stability of Ginsenosides Rg3 and CK Nano-emulsion | December 2023 | July 2024 | Allow | 7 | 1 | 0 | No | No |
| 18565770 | MANUFACTURING OF DIMERIC CONTRAST AGENTS | November 2023 | March 2025 | Allow | 16 | 3 | 0 | Yes | No |
| 18512708 | RADIOLABELED COMPOUNDS FOR IN VIVO IMAGING OF GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) AND TREATMENT OF GRPR-RELATED DISORDERS | November 2023 | November 2024 | Allow | 12 | 2 | 1 | No | No |
| 18474209 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | September 2023 | April 2025 | Allow | 19 | 2 | 0 | No | No |
| 18546989 | DUAL-TARGETING COMPOUND AND PREPARATION METHOD AND APPLICATION THEREOF | August 2023 | March 2024 | Allow | 7 | 1 | 0 | No | No |
| 18448609 | METHOD OF TREATING PROSTATE CANCER | August 2023 | June 2025 | Abandon | 23 | 4 | 0 | Yes | No |
| 18354282 | IMAGING AND RADIOTHERAPEUTICS AGENTS TARGETING FIBROBLAST-ACTIVATION PROTEIN-ALPHA (FAP-ALPHA) | July 2023 | January 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18257063 | TRUNCATED EVANS BLUE MODIFIED FIBROBLAST ACTIVATION PROTEIN INHIBITOR, PREPARATION METHOD AND APPLICATION THEREOF | June 2023 | January 2024 | Allow | 7 | 1 | 0 | No | No |
| 18189238 | MULTI-SIGNAL FLUORESCENT PROBE FOR EARLY DIAGNOSIS OF TUMORS, AND PREPARATION AND USE THEREOF | March 2023 | June 2023 | Allow | 3 | 0 | 0 | No | No |
| 18111704 | COMPOSITIONS INCLUDING PAFOLACIANINE FOR THE IDENTIFICATION OF MALIGNANT LESIONS | February 2023 | January 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 17907973 | NEAR-INFRARED FLUORESCENT PROBE SPECIFICALLY TARGETING TUMORS AS WELL AS SYNTHESIS METHOD AND USE THEREOF | August 2022 | May 2025 | Allow | 33 | 2 | 0 | No | No |
| 17884185 | Unassisted Robotic Surgery Employing Paramagnetic Halo Metallofullerenes as Minimally Invasive, Precision Scalpels or Micronization Particles through Magnetic Field Manipulation and Targeted Exenteration Patterned by Programmed 3D Imaging Using Needle or Magnetic Energy Access and Microelectronic Semiconducting in Non-stationary Wafer-less Space. | August 2022 | March 2023 | Allow | 7 | 2 | 1 | Yes | No |
| 17867030 | METHODS OF FUNCTIONALIZING NANOPARTICLES | July 2022 | January 2025 | Abandon | 30 | 5 | 0 | No | No |
| 17718812 | PSMA-TARGETING COMPOUNDS AND USES THEREOF | April 2022 | September 2022 | Allow | 5 | 1 | 0 | No | No |
| 17767039 | SYSTEMS AND METHODS OF ISOLATION OF GALLIUM-68 | April 2022 | September 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17697401 | RADIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR INFECTIOUS DISEASE DIAGNOSIS AND THERAPY | March 2022 | February 2023 | Abandon | 11 | 1 | 1 | No | No |
| 17697416 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | March 2022 | September 2022 | Allow | 6 | 0 | 1 | No | No |
| 17633843 | METHOD AND REAGENTS FOR DETECTING LUCIFERASE ACTIVITY | February 2022 | April 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17461860 | RADIOPHARMACEUTICAL AND METHODS | August 2021 | August 2022 | Allow | 11 | 1 | 0 | Yes | No |
| 17397022 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHOD | August 2021 | June 2022 | Allow | 10 | 2 | 0 | Yes | No |
| 17423589 | COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED OF A DIASTEREOISOMERICALLY ENRICHED PCTA AND SYNTHESIS METHOD | July 2021 | May 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17374984 | RADIOPHARMACEUTICAL AND METHODS | July 2021 | September 2022 | Allow | 14 | 2 | 0 | Yes | No |
| 17373987 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | July 2021 | March 2025 | Allow | 44 | 1 | 0 | No | No |
| 17371663 | NEAR-INFRARED FLUORESCENT CONTRAST BIOIMAGING AGENTS AND METHODS OF USE THEREOF | July 2021 | February 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17371587 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | July 2021 | August 2022 | Allow | 14 | 3 | 0 | Yes | No |
| 17369104 | MODIFIED NANODELIVERY SYSTEM AND METHOD FOR ENHANCED IN VIVO MEDICAL AND PRECLINICAL IMAGING | July 2021 | August 2024 | Allow | 37 | 0 | 0 | No | No |
| 17359490 | COMPOSITIONS AND METHODS FOR DETECTING ACE2 EXPRESSION PROFILES | June 2021 | December 2023 | Abandon | 29 | 1 | 0 | No | No |
| 17355286 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | June 2021 | November 2024 | Allow | 41 | 1 | 0 | No | No |
| 17331927 | Methods for Synthesis of Radionuclide Complex | May 2021 | February 2025 | Abandon | 44 | 2 | 0 | No | No |
| 17331113 | PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY | May 2021 | April 2024 | Allow | 34 | 1 | 0 | No | No |
| 17318802 | Organic Anion Transporting Peptide-Based Cancer Imaging and Therapy | May 2021 | April 2025 | Allow | 47 | 2 | 0 | No | No |
| 17233102 | MECHANICAL OPENING OF LIPID BILAYERS BY MOLECULAR NANOMACHINES | April 2021 | September 2022 | Allow | 17 | 4 | 0 | Yes | No |
| 17209121 | Stable, concentrated radionuclide complex solutions | March 2021 | December 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17209122 | Stable, concentrated radionuclide complex solutions | March 2021 | November 2023 | Abandon | 32 | 1 | 0 | No | No |
| 17204196 | ENHANCED SURGICAL VISUALIZATION OF VIABLE TISSUE AND PEPTIDES THEREFOR | March 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17199122 | GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS | March 2021 | March 2024 | Allow | 36 | 1 | 0 | Yes | No |
| 17185502 | Compounds and Methods of Making Compounds | February 2021 | February 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17127754 | ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | December 2020 | June 2024 | Allow | 41 | 3 | 0 | Yes | No |
| 17117424 | PHYSIOLOGICALLY STABLE FLUOROPHORE AND PERFORMING FLUORESCENCE PROBING | December 2020 | November 2023 | Allow | 35 | 2 | 0 | Yes | No |
| 17116596 | BISMUTH-IRON OXIDE CONTRAST AGENTS | December 2020 | May 2024 | Abandon | 41 | 2 | 0 | No | No |
| 16973254 | Pretreatment Method for Fluorescent Image Diagnosis | December 2020 | April 2025 | Allow | 52 | 3 | 0 | Yes | No |
| 17114195 | SYNTHESIS AND COMPOSITION OF NON-AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | December 2020 | April 2024 | Allow | 40 | 1 | 0 | No | No |
| 17112075 | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands | December 2020 | August 2023 | Allow | 32 | 1 | 0 | No | No |
| 17112497 | PSMA-TARGETED NIR DYES AND THEIR USES | December 2020 | October 2024 | Abandon | 47 | 3 | 0 | No | No |
| 17105308 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | November 2020 | July 2024 | Allow | 44 | 2 | 0 | Yes | No |
| 17057284 | ONE-STEP, FAST, 18F-19F ISOTOPIC EXCHANGE RADIOLABELING OF DIFLUORO-DIOXABORININS AND USE OF SUCH COMPOUNDS IN TREATMENT | November 2020 | March 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17057506 | RADIOLABELED MELANOCORTIN 1 RECEPTOR-SPECIFIC ALPHA-MELANOCYTE-STIMULATING HORMONE ANALOGUES FOR IMAGING OR THERAPY | November 2020 | March 2024 | Allow | 40 | 2 | 0 | No | No |
| 16950107 | HNQO1-ACTIVATABLE FLUORESCENT PROBE FOR IMAGING CANCER CELLS IN-VITRO AND IN-VIVO | November 2020 | December 2023 | Allow | 37 | 1 | 0 | No | No |
| 17092587 | ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | November 2020 | January 2023 | Allow | 26 | 1 | 0 | No | No |
| 17093184 | SPECIFIC CONJUGATION LINKERS, SPECIFIC IMMUNOCONJUGATES THEREOF, METHODS OF MAKING AND USES SUCH CONJUGATES THEREOF | November 2020 | August 2023 | Allow | 33 | 2 | 0 | No | No |
| 17050370 | NILE RED DERIVATIVES FOR IMPROVED RATIOMETRIC IMAGING FOR NERVE SPECIFIC CONTRAST | October 2020 | October 2024 | Abandon | 47 | 2 | 0 | No | No |
| 17074832 | RADIOLABELING AGENTS, METHODS OF MAKING, AND METHODS OF USE THEREOF | October 2020 | July 2023 | Abandon | 33 | 0 | 1 | No | No |
| 17047748 | CYCLOPHANES FOR LIVE-CELL IMAGING | October 2020 | June 2023 | Allow | 32 | 1 | 0 | No | No |
| 17046053 | TARGETING COMPOUNDS AND METHODS FOR THEIR PRODUCTION | October 2020 | December 2023 | Allow | 38 | 3 | 0 | No | No |
| 17060396 | DIMERIC CONTRAST AGENTS | October 2020 | June 2022 | Allow | 20 | 1 | 0 | Yes | No |
| 17042534 | USE OF BIS-IMINOBIOTIN COMPOUND FOR DRUG DELIVERY PURPOSES | September 2020 | June 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17042772 | FORMULATIONS AND KITS FOR RADIOTHERAPY AND DIAGNOSTIC IMAGING | September 2020 | March 2023 | Allow | 30 | 3 | 0 | No | No |
| 17029226 | PSMA-TARGETED NIR DYES AND THEIR USES | September 2020 | June 2022 | Allow | 21 | 1 | 0 | No | No |
| 17025711 | CA IX - NIR DYES AND THEIR USES | September 2020 | September 2022 | Allow | 24 | 1 | 0 | No | No |
| 16980252 | 177Lu-DOTA-HYNIC-iPSMA AS A THERAPEUTIC RADIOPHARMACEUTICAL TARGETING PROSTATE-SPECIFIC MEMBRANE ANTIGEN | September 2020 | August 2024 | Allow | 47 | 6 | 0 | Yes | No |
| 16971671 | POSITRON EMISSION TOMOGRAPHY IMAGING OF ACTIVATABLE BINDING POLYPEPTIDES AND RELATED COMPOSITIONS THEREOF | August 2020 | June 2025 | Abandon | 57 | 2 | 0 | No | Yes |
| 16970155 | HEPTAMETHINE CYANINES FOR USE AS FLUORESCENT MARKERS OF THE BILIARY AND RENAL SYSTEMS | August 2020 | June 2023 | Allow | 34 | 2 | 0 | No | No |
| 16990368 | MANGANESE-BASED CHELATE CONJUGATES FOR MOLECULAR MR IMAGING | August 2020 | April 2022 | Allow | 20 | 1 | 0 | No | No |
| 16967624 | COMPOUND FOR INTRAOPERATIVE MOLECULAR BIOIMAGING, METHOD OF MAKING THE SAME, USE THEREOF IN INTRAOPERATIVE MOLECULAR BIOIMAGING AND SURGICAL METHOD COMPRISING INTRAOPERATIVE MOLECULAR BIOIMAGING | August 2020 | June 2024 | Abandon | 47 | 2 | 0 | No | No |
| 16966182 | BIOINK COMPOSITION FOR DERMIS REGENERATION SHEET, METHOD FOR MANUFACTURING CUSTOMIZED DERMIS REGENERATION SHEET USING SAME, AND CUSTOMIZED DERMIS REGENERATION SHEET MANUFACTURED USING MANUFACTURING METHOD | July 2020 | February 2024 | Abandon | 42 | 1 | 1 | Yes | No |
| 16926807 | TARGETED PHOTOACOUSTIC AGENTS AND USES THEREOF | July 2020 | October 2023 | Abandon | 39 | 2 | 0 | No | No |
| 16919562 | Methods of Using C-Met Modulators | July 2020 | April 2022 | Allow | 22 | 1 | 0 | No | No |
| 16905702 | ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGE | June 2020 | February 2023 | Allow | 32 | 1 | 0 | No | No |
| 16905718 | ASSESSMENT OF IRON DEPOSITION POST MYOCARDIAL INFARCTION AS A MARKER OF MYOCARDIAL HEMORRHAGE | June 2020 | February 2023 | Allow | 32 | 1 | 0 | No | No |
| 16771061 | ANTICANCER FLUORESCENT SUBSTANCE DERIVED FROM NATURAL MATERIALS | June 2020 | July 2023 | Abandon | 37 | 3 | 0 | No | No |
| 16895263 | COMPRESSED SOLID COMPOSITION FOR MRI | June 2020 | December 2020 | Allow | 6 | 1 | 1 | Yes | No |
| 16894794 | METHOD AND DEVICE FOR PRODUCING OPTIMIZED LIPID-BASED MICRO/NANO-BUBBLES | June 2020 | March 2022 | Abandon | 21 | 1 | 1 | No | No |
| 16893330 | CROSSLINKED HYDROGEL COMPOSITIONS FOR REGULATING STATES OF ENCAPSULATED CANCER CELLS | June 2020 | April 2024 | Allow | 47 | 2 | 1 | Yes | No |
| 16892060 | TREATMENT OF METAHNOGENIC BACTERIA AS A THERAPY FOR CHRONIC LUNG DISEASE | June 2020 | March 2024 | Abandon | 45 | 3 | 0 | Yes | No |
| 16891181 | Radioactive Phospholipid Metal Chelates for Cancer Imaging and Therapy | June 2020 | August 2021 | Allow | 14 | 1 | 0 | No | No |
| 16887754 | METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | May 2020 | January 2022 | Abandon | 20 | 1 | 0 | No | No |
| 16888114 | METHODS FOR PRESERVING A SUBJECT AND USING IMAGING CONTRAST AGENTS | May 2020 | September 2023 | Allow | 40 | 4 | 0 | Yes | No |
| 16766619 | GADOLINIUM BEARING PCTA-BASED CONTRAST AGENTS | May 2020 | February 2021 | Allow | 8 | 1 | 0 | Yes | No |
| 16879851 | DYE-PROTEIN COMPLEX FOR NIR II AND PHOTOACOUSTIC IMAGING | May 2020 | February 2023 | Abandon | 33 | 3 | 0 | Yes | No |
| 16765927 | A DOUBLE-LABELED PROBE FOR MOLECULAR IMAGING AND USE THEREOF | May 2020 | December 2022 | Allow | 31 | 2 | 0 | No | No |
| 16765729 | PSMA ligands for imaging and endoradiotherapy | May 2020 | April 2022 | Allow | 23 | 1 | 0 | No | No |
| 16876606 | SIZE-VARYING BUBBLE COMPLEX AND METHOD OF PREPARING THE SAME | May 2020 | August 2022 | Allow | 27 | 1 | 1 | No | No |
| 16848586 | MEROCYANINE-BASED COMPOUND AND BIOMOLECULAR LABELING DYE, KIT AND CONTRAST AGENT COMPOSITION COMPRISING SAME | April 2020 | February 2022 | Allow | 22 | 0 | 0 | No | No |
| 16754986 | SYSTEM AND METHOD TO CONTROL NUCLEATION OF BUBBLES | April 2020 | January 2023 | Allow | 33 | 3 | 0 | Yes | No |
| 16831899 | SALINE NANODROPLETS FOR RADIO-FREQUENCY-ACOUSTIC MOLECULAR IMAGING | March 2020 | March 2022 | Abandon | 24 | 1 | 0 | No | No |
| 16828119 | COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS | March 2020 | September 2022 | Abandon | 30 | 2 | 0 | No | Yes |
| 16827606 | Stable, concentrated radionuclide complex solutions | March 2020 | January 2023 | Allow | 34 | 2 | 0 | No | No |
| 16824139 | NOVEL DEUTERIUM SUBSTITUTED POSITRON EMISSION TOMOGRAPHY (PET) IMAGING AGENTS AND THEIR PHARMACOLOGICAL APPLICATION | March 2020 | April 2021 | Allow | 13 | 0 | 0 | No | No |
| 16820052 | PSMA TARGETED FLUORESCENT AGENTS FOR IMAGE GUIDED SURGERY | March 2020 | January 2021 | Allow | 10 | 1 | 1 | Yes | No |
| 16816118 | Near-Infrared Dyes And Conjugates For Targeting Tumors | March 2020 | April 2024 | Allow | 50 | 4 | 0 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner PERREIRA, MELISSA JEAN.
With a 21.4% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner PERREIRA, MELISSA JEAN works in Art Unit 1618 and has examined 912 patent applications in our dataset. With an allowance rate of 50.1%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 39 months.
Examiner PERREIRA, MELISSA JEAN's allowance rate of 50.1% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by PERREIRA, MELISSA JEAN receive 2.51 office actions before reaching final disposition. This places the examiner in the 85% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by PERREIRA, MELISSA JEAN is 39 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +27.2% benefit to allowance rate for applications examined by PERREIRA, MELISSA JEAN. This interview benefit is in the 78% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 13.9% of applications are subsequently allowed. This success rate is in the 5% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 35.9% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 40% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 57.6% of appeals filed. This is in the 26% percentile among all examiners. Of these withdrawals, 59.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 67.7% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 3.6% of allowed cases (in the 85% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.